- 米国企業
- Theravance Biopharma, Inc.
Theravance Biopharma, Inc.TBPH
| 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 | 2023年
12月31日 |
|---|
| Net (loss) income | -237 | -182 | -191 | -285 | -216 | -236 | -278 | -199 | 872 | -55 |
|---|
| Less: Net income from discontinued operations | - | - | - | - | - | - | - | - | 965 | - |
|---|
| Net loss from continuing operations | - | - | - | - | - | - | - | - | -93 | -55 |
|---|
| Depreciation and amortization | - | - | - | - | - | 6 | 7 | 6 | 4 | 2 |
|---|
| Amortization and accretion income, net | - | - | - | - | - | 3 | 1 | -0 | 1 | 2 |
|---|
| Future royalty payment contingency interest accretion | - | - | - | - | - | - | - | - | 1 | 2 |
|---|
| Share-based compensation | 43 | 54 | 41 | 49 | 51 | 60 | 63 | 62 | 40 | 25 |
|---|
| (Gain) loss on disposal of property and equipment | - | - | - | - | - | - | - | -0 | 0 | -1 |
|---|
| Gain on sale of Velusetrag | - | - | - | - | 6 | - | - | - | 3 | - |
|---|
| Gain on sale of Velusetrag | - | - | - | - | 6 | - | - | - | 3 | - |
|---|
| (Gain) loss on disposal of property and equipment | - | - | - | - | - | - | - | -0 | 0 | -1 |
|---|
| Amortization of right-of-use assets | - | - | - | - | - | - | - | - | 4 | 4 |
|---|
| Gain from lease modification | - | - | - | - | - | - | - | 2 | - | - |
|---|
| Deferred income taxes | - | - | - | - | - | - | - | - | - | 3 |
|---|
| Loss on extinguishment of debt | - | - | - | - | - | - | -15 | - | -3 | - |
|---|
| Other | - | 0 | -0 | -0 | 0 | -0 | 0 | -0 | - | - |
|---|
| Receivables from collaborative and licensing arrangements | - | 33 | -26 | -2 | 3 | 12 | -6 | -2 | 3 | 1 |
|---|
| Prepaid clinical and development services | - | - | - | - | - | - | 18 | -10 | -9 | 1 |
|---|
| Other prepaid and current assets | - | -1 | -3 | 1 | 2 | 1 | 2 | -3 | 1 | 4 |
|---|
| Right-of-use lease assets | - | - | - | - | - | - | - | - | -4 | -0 |
|---|
| Other assets | 0 | 1 | -0 | 0 | -0 | 0 | 1 | 1 | 4 | 1 |
|---|
| Accounts payable | 4 | 9 | -16 | 4 | 4 | -4 | 4 | -4 | -2 | 0 |
|---|
| Increase (Decrease) in Accrued Liabilities | 12 | -1 | 17 | 8 | -11 | 11 | 6 | -37 | -14 | -7 |
|---|
| Accrued interest payable | - | - | - | - | - | 3 | -2 | -0 | -1 | - |
|---|
| Deferred revenue | - | - | - | - | 69 | -31 | -26 | -11 | -0 | -0 |
|---|
| Operating lease liabilities | - | - | - | - | - | - | - | -2 | -1 | -3 |
|---|
| Unrecognized tax benefits | - | - | - | - | - | - | - | - | 64 | 1 |
|---|
| Other long-term liabilities | 1 | 1 | 10 | 24 | -10 | -5 | -8 | 1 | -1 | 8 |
|---|
| Receivables from collaborative and licensing arrangements | - | 33 | -26 | -2 | 3 | 12 | -6 | -2 | 3 | 1 |
|---|
| Prepaid clinical and development services | - | - | - | - | - | - | 18 | -10 | -9 | 1 |
|---|
| Other prepaid and current assets | - | -1 | -3 | 1 | 2 | 1 | 2 | -3 | 1 | 4 |
|---|
| Right-of-use lease assets | - | - | - | - | - | - | - | - | -4 | -0 |
|---|
| Other assets | 0 | 1 | -0 | 0 | -0 | 0 | 1 | 1 | 4 | 1 |
|---|
| Accounts payable | 4 | 9 | -16 | 4 | 4 | -4 | 4 | -4 | -2 | 0 |
|---|
| Increase (Decrease) in Accrued Liabilities | 12 | -1 | 17 | 8 | -11 | 11 | 6 | -37 | -14 | -7 |
|---|
| Accrued interest payable | - | - | - | - | - | 3 | -2 | -0 | -1 | - |
|---|
| Deferred revenue | - | - | - | - | 69 | -31 | -26 | -11 | -0 | -0 |
|---|
| Operating lease liabilities | - | - | - | - | - | - | - | -2 | -1 | -3 |
|---|
| Unrecognized tax benefits | - | - | - | - | - | - | - | - | 64 | 1 |
|---|
| Other long-term liabilities | 1 | 1 | 10 | 24 | -10 | -5 | -8 | 1 | -1 | 8 |
|---|
| Net cash used in operating activities - continuing operations | -175 | -169 | -99 | - | - | - | - | - | -2 | -27 |
|---|
| Net cash used in operating activities - discontinued operations | - | - | - | - | - | - | - | - | -185 | - |
|---|
| Net cash used in operating activities | - | - | - | -201 | -113 | -238 | -250 | -208 | -187 | -27 |
|---|
| Purchases of property and equipment | - | - | - | 2 | 7 | 3 | 7 | 3 | 1 | 2 |
|---|
| Purchases of marketable securities | - | - | - | - | 183 | 424 | 402 | 158 | 103 | 135 |
|---|
| Maturities of marketable securities | 66 | 187 | 91 | 235 | 347 | 339 | 399 | 286 | 158 | 31 |
|---|
| Sale of short-term investments and marketable securities | - | - | - | - | - | - | - | - | 0 | 71 |
|---|
| Proceeds from the sale of Velusetrag | - | - | - | - | 20 | 5 | - | - | 3 | - |
|---|
| Proceeds from the sale of property and equipment | - | - | - | - | - | - | 0 | 0 | 2 | 2 |
|---|
| Net cash (used in) provided by investing activities - continuing operations | -106 | 111 | -148 | - | - | - | - | - | 59 | -33 |
|---|
| Net cash provided by investing activities - discontinued operations | - | - | - | - | - | - | - | - | 1,095 | - |
|---|
| Net cash (used in) provided by investing activities | - | - | - | -56 | 177 | -83 | 11 | 124 | 1,154 | -33 |
|---|
| Ordinary share repurchases | - | - | - | - | - | - | - | - | 129 | 197 |
|---|
| Proceeds from Issuance of Common Stock | - | - | 253 | - | - | - | 140 | 108 | - | - |
|---|
| Proceeds from ampreloxetine funding, net | - | - | - | - | - | - | - | - | 24 | - |
|---|
| Proceeds from ampreloxetine funding, net | - | - | - | - | - | - | - | - | 24 | - |
|---|
| 2035 notes | - | - | - | - | - | - | - | - | 400 | - |
|---|
| 2023 notes | - | - | - | - | - | - | - | - | 232 | - |
|---|
| Principal payment on notes | - | - | - | - | - | 2 | 235 | 11 | - | - |
|---|
| 2035 notes | - | - | - | - | - | - | - | - | 400 | - |
|---|
| 2023 notes | - | - | - | - | - | - | - | - | 232 | - |
|---|
| Principal payment on notes | - | - | - | - | - | 2 | 235 | 11 | - | - |
|---|
| Proceeds from Stock Plans | - | 3 | 3 | 4 | 4 | 3 | 4 | 3 | 1 | 1 |
|---|
| Proceed from issuance of 2035 notes | - | - | - | - | - | - | 380 | - | - | - |
|---|
| Repurchase of shares to satisfy tax withholding | 0 | 1 | 4 | 9 | 10 | 3 | 10 | 9 | 3 | 3 |
|---|
| Proceeds from Stock Plans | - | 3 | 3 | 4 | 4 | 3 | 4 | 3 | 1 | 1 |
|---|
| Net cash used in financing activities - continuing operations | 371 | 81 | 479 | - | - | - | - | - | -739 | -199 |
|---|
| Proceeds from option exercises | - | - | 4 | 6 | 1 | 3 | 1 | 0 | - | - |
|---|
| Net cash used in financing activities - discontinued operations | - | - | - | - | - | - | - | - | -20 | - |
|---|
| Repurchase of shares to satisfy tax withholding | 0 | 1 | 4 | 9 | 10 | 3 | 10 | 9 | 3 | 3 |
|---|
| Net cash used in financing activities | - | - | - | 2 | 225 | 1 | 263 | 92 | -759 | -199 |
|---|
| Net cash used in financing activities - continuing operations | 371 | 81 | 479 | - | - | - | - | - | -739 | -199 |
|---|
| Net cash used in financing activities - discontinued operations | - | - | - | - | - | - | - | - | -20 | - |
|---|
| Net cash used in financing activities | - | - | - | 2 | 225 | 1 | 263 | 92 | -759 | -199 |
|---|
| Net (decrease) increase in cash, cash equivalents, and restricted cash | - | - | - | - | 289 | -320 | 23 | 8 | 208 | -259 |
|---|
| Cash paid for interest | - | - | - | 7 | 7 | 26 | 24 | 39 | 22 | - |
|---|
| Income Taxes Paid, Net | - | - | -9 | 5 | -7 | 0 | 0 | -4 | 118 | 0 |
|---|
| Net (loss) income | -237 | -182 | -191 | -285 | -216 | -236 | -278 | -199 | 872 | -55 |
|---|
| Less: Net income from discontinued operations | - | - | - | - | - | - | - | - | 965 | - |
|---|
| Net loss from continuing operations | - | - | - | - | - | - | - | - | -93 | -55 |
|---|
| Depreciation and amortization | - | - | - | - | - | 6 | 7 | 6 | 4 | 2 |
|---|
| Amortization and accretion income, net | - | - | - | - | - | 3 | 1 | -0 | 1 | 2 |
|---|
| Future royalty payment contingency interest accretion | - | - | - | - | - | - | - | - | 1 | 2 |
|---|
| Share-based compensation | 43 | 54 | 41 | 49 | 51 | 60 | 63 | 62 | 40 | 25 |
|---|
| (Gain) loss on disposal of property and equipment | - | - | - | - | - | - | - | -0 | 0 | -1 |
|---|
| Gain on sale of Velusetrag | - | - | - | - | 6 | - | - | - | 3 | - |
|---|
| Gain on sale of Velusetrag | - | - | - | - | 6 | - | - | - | 3 | - |
|---|
| (Gain) loss on disposal of property and equipment | - | - | - | - | - | - | - | -0 | 0 | -1 |
|---|
| Amortization of right-of-use assets | - | - | - | - | - | - | - | - | 4 | 4 |
|---|
| Gain from lease modification | - | - | - | - | - | - | - | 2 | - | - |
|---|
| Deferred income taxes | - | - | - | - | - | - | - | - | - | 3 |
|---|
| Loss on extinguishment of debt | - | - | - | - | - | - | -15 | - | -3 | - |
|---|
| Other | - | 0 | -0 | -0 | 0 | -0 | 0 | -0 | - | - |
|---|
| Receivables from collaborative and licensing arrangements | - | 33 | -26 | -2 | 3 | 12 | -6 | -2 | 3 | 1 |
|---|
| Prepaid clinical and development services | - | - | - | - | - | - | 18 | -10 | -9 | 1 |
|---|
| Other prepaid and current assets | - | -1 | -3 | 1 | 2 | 1 | 2 | -3 | 1 | 4 |
|---|
| Right-of-use lease assets | - | - | - | - | - | - | - | - | -4 | -0 |
|---|
| Other assets | 0 | 1 | -0 | 0 | -0 | 0 | 1 | 1 | 4 | 1 |
|---|
| Accounts payable | 4 | 9 | -16 | 4 | 4 | -4 | 4 | -4 | -2 | 0 |
|---|
| Increase (Decrease) in Accrued Liabilities | 12 | -1 | 17 | 8 | -11 | 11 | 6 | -37 | -14 | -7 |
|---|
| Accrued interest payable | - | - | - | - | - | 3 | -2 | -0 | -1 | - |
|---|
| Deferred revenue | - | - | - | - | 69 | -31 | -26 | -11 | -0 | -0 |
|---|
| Operating lease liabilities | - | - | - | - | - | - | - | -2 | -1 | -3 |
|---|
| Unrecognized tax benefits | - | - | - | - | - | - | - | - | 64 | 1 |
|---|
| Other long-term liabilities | 1 | 1 | 10 | 24 | -10 | -5 | -8 | 1 | -1 | 8 |
|---|
| Receivables from collaborative and licensing arrangements | - | 33 | -26 | -2 | 3 | 12 | -6 | -2 | 3 | 1 |
|---|
| Prepaid clinical and development services | - | - | - | - | - | - | 18 | -10 | -9 | 1 |
|---|
| Other prepaid and current assets | - | -1 | -3 | 1 | 2 | 1 | 2 | -3 | 1 | 4 |
|---|
| Right-of-use lease assets | - | - | - | - | - | - | - | - | -4 | -0 |
|---|
| Other assets | 0 | 1 | -0 | 0 | -0 | 0 | 1 | 1 | 4 | 1 |
|---|
| Accounts payable | 4 | 9 | -16 | 4 | 4 | -4 | 4 | -4 | -2 | 0 |
|---|
| Increase (Decrease) in Accrued Liabilities | 12 | -1 | 17 | 8 | -11 | 11 | 6 | -37 | -14 | -7 |
|---|
| Accrued interest payable | - | - | - | - | - | 3 | -2 | -0 | -1 | - |
|---|
| Deferred revenue | - | - | - | - | 69 | -31 | -26 | -11 | -0 | -0 |
|---|
| Operating lease liabilities | - | - | - | - | - | - | - | -2 | -1 | -3 |
|---|
| Unrecognized tax benefits | - | - | - | - | - | - | - | - | 64 | 1 |
|---|
| Other long-term liabilities | 1 | 1 | 10 | 24 | -10 | -5 | -8 | 1 | -1 | 8 |
|---|
| Net cash used in operating activities - continuing operations | -175 | -169 | -99 | - | - | - | - | - | -2 | -27 |
|---|
| Net cash used in operating activities - discontinued operations | - | - | - | - | - | - | - | - | -185 | - |
|---|
| Net cash used in operating activities | - | - | - | -201 | -113 | -238 | -250 | -208 | -187 | -27 |
|---|
| Purchases of property and equipment | - | - | - | 2 | 7 | 3 | 7 | 3 | 1 | 2 |
|---|
| Purchases of marketable securities | - | - | - | - | 183 | 424 | 402 | 158 | 103 | 135 |
|---|
| Maturities of marketable securities | 66 | 187 | 91 | 235 | 347 | 339 | 399 | 286 | 158 | 31 |
|---|
| Sale of short-term investments and marketable securities | - | - | - | - | - | - | - | - | 0 | 71 |
|---|
| Proceeds from the sale of Velusetrag | - | - | - | - | 20 | 5 | - | - | 3 | - |
|---|
| Proceeds from the sale of property and equipment | - | - | - | - | - | - | 0 | 0 | 2 | 2 |
|---|
| Net cash (used in) provided by investing activities - continuing operations | -106 | 111 | -148 | - | - | - | - | - | 59 | -33 |
|---|
| Net cash provided by investing activities - discontinued operations | - | - | - | - | - | - | - | - | 1,095 | - |
|---|
| Net cash (used in) provided by investing activities | - | - | - | -56 | 177 | -83 | 11 | 124 | 1,154 | -33 |
|---|
| Ordinary share repurchases | - | - | - | - | - | - | - | - | 129 | 197 |
|---|
| Proceeds from Issuance of Common Stock | - | - | 253 | - | - | - | 140 | 108 | - | - |
|---|
| Proceeds from ampreloxetine funding, net | - | - | - | - | - | - | - | - | 24 | - |
|---|
| Proceeds from ampreloxetine funding, net | - | - | - | - | - | - | - | - | 24 | - |
|---|
| 2035 notes | - | - | - | - | - | - | - | - | 400 | - |
|---|
| 2023 notes | - | - | - | - | - | - | - | - | 232 | - |
|---|
| Principal payment on notes | - | - | - | - | - | 2 | 235 | 11 | - | - |
|---|
| 2035 notes | - | - | - | - | - | - | - | - | 400 | - |
|---|
| 2023 notes | - | - | - | - | - | - | - | - | 232 | - |
|---|
| Principal payment on notes | - | - | - | - | - | 2 | 235 | 11 | - | - |
|---|
| Proceeds from Stock Plans | - | 3 | 3 | 4 | 4 | 3 | 4 | 3 | 1 | 1 |
|---|
| Proceed from issuance of 2035 notes | - | - | - | - | - | - | 380 | - | - | - |
|---|
| Repurchase of shares to satisfy tax withholding | 0 | 1 | 4 | 9 | 10 | 3 | 10 | 9 | 3 | 3 |
|---|
| Proceeds from Stock Plans | - | 3 | 3 | 4 | 4 | 3 | 4 | 3 | 1 | 1 |
|---|
| Net cash used in financing activities - continuing operations | 371 | 81 | 479 | - | - | - | - | - | -739 | -199 |
|---|
| Proceeds from option exercises | - | - | 4 | 6 | 1 | 3 | 1 | 0 | - | - |
|---|
| Net cash used in financing activities - discontinued operations | - | - | - | - | - | - | - | - | -20 | - |
|---|
| Repurchase of shares to satisfy tax withholding | 0 | 1 | 4 | 9 | 10 | 3 | 10 | 9 | 3 | 3 |
|---|
| Net cash used in financing activities | - | - | - | 2 | 225 | 1 | 263 | 92 | -759 | -199 |
|---|
| Net cash used in financing activities - continuing operations | 371 | 81 | 479 | - | - | - | - | - | -739 | -199 |
|---|
| Net cash used in financing activities - discontinued operations | - | - | - | - | - | - | - | - | -20 | - |
|---|
| Net cash used in financing activities | - | - | - | 2 | 225 | 1 | 263 | 92 | -759 | -199 |
|---|
| Net (decrease) increase in cash, cash equivalents, and restricted cash | - | - | - | - | 289 | -320 | 23 | 8 | 208 | -259 |
|---|
| Cash paid for interest | - | - | - | 7 | 7 | 26 | 24 | 39 | 22 | - |
|---|
| Income Taxes Paid, Net | - | - | -9 | 5 | -7 | 0 | 0 | -4 | 118 | 0 |
|---|